EUVIMEDEUVIMED entdecken
Open Access

N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy

Matthew E Griffin iD, Taku Tsukidate iD, Howard C Hang iD

ACS Chemical Biology · 2023

DOI: 10.1021/acschembio.3c00085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2023. Verfasst von Matthew E Griffin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, Scripps Research, La Jolla, California 92037, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adjuvants, Immunologic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Melanoma Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The characterization of microbiota mechanisms in health and disease has reinvigorated pattern recognition receptors as prominent targets for immunotherapy. Notably, our recent studies on Enterococcus species revealed peptidoglycan remodeling and activation of NOD2 as key mechanisms for microbiota enhancement of immune checkpoint inhibitor therapy. Inspired by this work and other studies of NOD2 activation, we performed in silico ligand screening and developed N-arylpyrazole dipeptides as novel NOD2 agonists. Importantly, our N-arylpyrazole NOD2 agonist is enantiomer-specific and effective at promoting immune checkpoint inhibitor therapy and requires NOD2 for activity in vivo. Given the significant functions of NOD2 in innate and adaptive immunity, these next-generation agonists afford new therapeutic leads and adjuvants for a variety of NOD2-responsive diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdjuvants, ImmunologicReceptors, Pattern RecognitionAdaptive ImmunityImmunity, InnateNod2 Signaling Adaptor Protein

Substanzen

Immune Checkpoint InhibitorsAdjuvants, ImmunologicReceptors, Pattern RecognitionNod2 Signaling Adaptor Protein

Autor:innen und Institutionen

  • Department of Immunology and Microbiology, Scripps Research, La Jolla, California 92037, United States.
  • Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States.
  • Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller University, New York, New York 10065, United States.
  • Department of Chemistry, Scripps Research, La Jolla, California 92037, United States.

ORCID-Profile: Matthew E Griffin, Taku Tsukidate, Howard C Hang

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Melanoma Research Foundation
  • Rockefeller University
  • Hope Funds for Cancer Research
  • Takenaka Scholarship Foundation

Zitieren

APA

Griffin, M. E., Tsukidate, T., & Hang, H. C. (2023). N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00085

Vancouver

Griffin ME, Tsukidate T, Hang HC. N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy. ACS Chemical Biology. 2023. doi:10.1021/acschembio.3c00085

BibTeX
@article{Griffin2023,
  author = {Griffin, Matthew E and Tsukidate, Taku and Hang, Howard C},
  title = {N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy},
  journal = {ACS Chemical Biology},
  year = {2023},
  doi = {10.1021/acschembio.3c00085}
}
Kostenlos starten →